Panobinostat (LBH589)

製品コードS1030 別名:NVP-LBH589

Panobinostat (LBH589)化学構造

分子量(MW):349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

サイズ 価格(税別)  
JPY 14940.00
JPY 44820.00
JPY 111220.00

文献中Selleckの製品使用例(52)

カスタマーフィードバック(12)

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
ターゲット
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
体外試験

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK5TW0xNTFyIN88US=> MlvTNE01KGR? MXvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVLzeW0zOjZ5MEK3PFQ>
HepG2 NWCyWG9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTZNE0yOCEQvF2= NEjNdosxNTRiZB?= MkjtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXv0U|U4OjZ5MEK3PFQ>
HT29 M4\2NmZ2dmO2aX;uJGF{e2G7 MluxOVDDqG6P NXf0bVl[OjRvN{KgbC=> MUDpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFQ5yqCqwrC= MlzyNlY4ODJ5OES=
HepG2 MXfGeY5kfGmxbjDBd5NigQ>? MVS1NOKhdk1? NVvTUmpEOjRvN{KgbC=> NGXHVnNqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDJ2wrDoxsA> MXOyOlcxOjd6NB?=
HCC827 M3;pUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu1dY82NzdwNT:xNEBvVQ>? MY[3NuKhcA>? M2f5SmROW09? MlXl[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? NWXRRoVNOjZ4N{W0PFQ>
A549  NF\vWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjYfYgyOC9zNT:yNEBvVQ>? M4rYOFczyqCq NEjmOIZFVVOR NGDyRpVmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= NGTISJgzPjZ5NUS4OC=>
NCI-H460  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqxNVAwOjBxM{Cgcm0> MlLaO|LDqGh? NYDOTZVITE2VTx?= M1rweYVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk MljZNlY3PzV2OES=
J89GFP M4C5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoriSG1UV8Li NXT1S25STUN3ME20PU45PSEEsTCxNk43PSCwTR?= MXmyOlU3OzV4OB?=
THP89GFP M4HCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPnSG1UV8Li MYLFR|UxRTF7LkO0JOKyKDZwNEOgcm0> MWSyOlU3OzV4OB?=
SK-NEP-1 M4rTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUewMlAy6oDVMUCuNEDPxE1? M4TxWVI1KGh? MUDEUXNQyqB? M2LKS2lEPTB;N{[uN|Qhdk1? M4P4WlI3OTd4MkG5
G401 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTv[YkxNjBz4pETNVAvOCEQvF2= M3HOTFI1KGh? MkTBSG1UV8Li MXrJR|UxRTF2Mz6wNkBvVQ>? MlfnNlYyPzZ{MUm=
SK-NEP-1 NXrWfJV{S2WubDDWbYFjcWyrdImgRZN{[Xl? MVe1NEBvVQ>? M3H1bFHjiJN2IHS= MWnEUXNQyqB? MWfy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M1TNUlI3OTd4MkG5
G401 MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEKySYo2OCCwTR?= NGXBOW0y6oDVNDDk M3LiWmROW00EoB?= Ml3KdoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz NFfMT|kzPjF5NkKxPS=>
SK-NEP-1 NWW2O|RvSXCxcITvd4l{KEG|c3H5 NU\TcndMPTBxMUCwJI5O NGPWS2IzPCCq NFTpN5hFVVORwrC= NH7PXJJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4DOWlI3OTd4MkG5
G401 Mkj0RZBweHSxc3nzJGF{e2G7 MXO1NE8yODBibl2= MUCyOEBp NF3PTlhFVVORwrC= MmDLbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoTENlYyPzZ{MUm=
SK-NEP-1 M2TESWZ2dmO2aX;uJGF{e2G7 NFrqTWI2OC9zMECgcm0> NYP6ZYFYOjRiaB?= NHnHSopFVVORwrC= NIXCeIl{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w M3O3XlI3OTd4MkG5
G401 M2Owc2Z2dmO2aX;uJGF{e2G7 NUf3cnRuPTBxMUCwJI5O Mn;RNlQhcA>? NIXTWppFVVORwrC= M4CzbZNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? MoPlNlYyPzZ{MUm=
SK-NEP-1 Mn7GSpVv[3Srb36gRZN{[Xl? NInwd5A2OC9zMECgcm0> MnnVNlQhcA>? Mn[zSG1UV8Li NWrtbJNjcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? NIjkXVEzPjF5NkKxPS=>
G401 NWXlcYJyTnWwY4Tpc44hSXO|YYm= MVO1NE8yODBibl2= MnvpNlQhcA>? MUHEUXNQyqB? NY\CRlRrcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? M{XtXFI3OTd4MkG5
RPMI 8226 MlW5R4VtdCCVdYL2bZZidCCDc4PhfS=> M33IWlIwPC94IH7N MXW0PQKBkWh? MUXpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp NGm2fXczPjByMEK5Ni=>
OPM2 M2\OOWNmdGxiU4Xyeol3[WxiQYPzZZk> M2Di[lIwPC94IH7N NHv2eJk1QOLCiXi= NWHTeYVbcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NXXUWI5OOjZyMECyPVI>
U266 NVTLPHNVS2WubDDTeZJ3cX[jbDDBd5NigQ>? NH61XpUzNzRxNjDuUS=> MVe0PQKBkWh? NW\SfXlHcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NGSwWZozPjByMEK5Ni=>
H929 MojXR4VtdCCVdYL2bZZidCCDc4PhfS=> M{G5d|IwPC94IH7N MXO0PQKBkWh? MljxbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? M2TuNFI3ODByMkmy
RPMI 8226  MmK4RZBweHSxc3nzJGF{e2G7 M1rNe|TjiImwTR?= M3noTlI1NzR6IHi= MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz MVOyOlAxODJ7Mh?=
HCC827 NWHnUpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjuNWtDOTBibl2= NFzzZWk1QCCq M1;pbWROW09? MWPlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? M{PxRVI2QTR2NkG3
NCI-H23 NIC1R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yxTFExKG6P MVy0PEBp MXjEUXNQ Mm\D[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? MoTSNlU6PDR4MUe=
AML3 NEXtPJpHfW6ldHnvckBCe3OjeR?= NUXvd3F3OC1zIN88US=> NH3UbWgzPMLiaB?= M2GzUYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4H0U|I2PjF{OUSx
ML-1 NVjJSoU6TnWwY4Tpc44hSXO|YYm= MnLaNE0yKM7:TR?= MmPsNlTDqGh? MWTpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWCyOVYyOjl2MR?=
RPMI-8226vr10  NH7ZSHpHfW6ldHnvckBCe3OjeR?= NX3VeIdmOC1zIN88US=> MWKyOOKhcA>? M1n6fIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVHxTVNEOjV4MUK5OFE>
ML-1 NUnSTFNLTnWwY4Tpc44hSXO|YYm= M2G3NlEh|ryP NVy0dpVZOjUEoHi= MkHEbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUA1NW[xbHS= M2PuVVI2PjF{OUSx
RPMI-8226vr10  MknZSpVv[3Srb36gRZN{[Xl? MnTiNUDPxE1? MXSyOOKhcA>? MVTpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk NYfLe5F[OjV4MUK5OFE>
SK-N-BE (2) NYDkW4RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTNRXQzPOLCiXi= M2mzT2lEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= M37l[FI2OzB6OUG2
SK-N-BE (2), PAN  MK MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUewTYRKOjUkgJno NFnq[|JKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= M2rhc|I2OzB6OUG2
SK-N-BE (2), MK  PAN M{T3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiwUHQzPOLCiXi= MX7JR|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P Mn;5NlU{ODh7MU[=
SK-N-AS M2jWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\NcVI16oDLaB?= MV3JR|UxRTN5LkJihKnDueLCiUKuOEBvVQ>? M2PONFI2OzB6OUG2
SK-N-DZ NInFeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLsOZdPOjUkgJno M1jZT2lEPTB;MUeuNgKBkcLz4pEJNE41KG6P MV[yOVMxQDlzNh?=
Caki-1 NESxVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfHO2YyOC9{NT:1NEBvVQ>? NVnHc2MyPDhiaB?= MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NYLnVGp5OjV{N{mxPVE>
ACHN MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqyNVAwOjVxNUCgcm0> MYK0PEBp NHj3XldqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NHrxdlIzPTJ5OUG5NS=>
769-P M3zJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOxNE8zPS93MDDuUS=> Mk\pOFghcA>? NF3GSVdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NHXPdZozPTJ5OUG5NS=>
786-O  MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGxNE8zPS93MDDuUS=> MUW0PEBp M3q1fIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= MYOyOVI4QTF7MR?=
Caki-1 M2\mZmFxd3C2b4Ppd{BCe3OjeR?= NX3ZcHlsPTBibl2= M3f6OFQ5KGh? M4DNS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ M2fEZVI2Ojd7MUmx
ACHN NVq4W5VSSXCxcITvd4l{KEG|c3H5 MlfLOVAhdk1? Ml7JOFghcA>? NXnBdGJMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= NW\wcXFzOjV{N{mxPVE>
769-P M{jXZWFxd3C2b4Ppd{BCe3OjeR?= NWrGSooyPTBibl2= MWS0PEBp MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? NXfscFN6OjV{N{mxPVE>
786-O  NYrxS5N3SXCxcITvd4l{KEG|c3H5 Mni2OVAhdk1? M4i2clQ5KGh? MYfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? NXPBRnpyOjV{N{mxPVE>
Caki-1 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvrNlUwPTBibl2= MXi0PEBp MXfEUXNQ NXfZcGxycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> Ml2yNlUyPzZ|NUS=
ACHN M3nsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fxRlI2NzVyIH7N MUW0PEBp MnTXSG1UVw>? NI[yNFdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni MVeyOVE4PjN3NB?=
769-P M{\QVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zHR|I2NzVyIH7N MYC0PEBp MWTEUXNQ NHnsTIZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni MnzYNlUyPzZ|NUS=
Caki-1 MnO1R49td267IF\vdo1ifGmxbjDBd5NigQ>? Mn30OVAhdk1? Ml\WO{0yPCCm M1nES2ROW09? MYLzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> NUDtdo95OjVzN{[zOVQ>
ACHN NH\afmZEd2yxbomgSo9zdWG2aX;uJGF{e2G7 MoLHOVAhdk1? NIrCcY84NTF2IHS= M2DzdmROW09? MmPud5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NUjkXZN4OjVzN{[zOVQ>
769-P NWXYVYpLS2:ub375JGZwem2jdHnvckBCe3OjeR?= MoLGOVAhdk1? MmrnO{0yPCCm NEDr[WJFVVOR MVjzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MmjENlUyPzZ|NUS=
Caki-1 NVjZOHJ3SXCxcITvd4l{KEG|c3H5 MXe1NEBvVQ>? MYq0PEBp NUTvVIFQTE2VTx?= NVP1dWZFcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYGyOVE4PjN3NB?=
ACHN MoXQRZBweHSxc3nzJGF{e2G7 M17BSlUxKG6P MY[0PEBp MX3EUXNQ NUmw[op1cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MV[yOVE4PjN3NB?=
769-P M4TMeGFxd3C2b4Ppd{BCe3OjeR?= NWribJhzPTBibl2= MVG0PEBp NVfQRWNzTE2VTx?= MXjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MWCyOVE4PjN3NB?=
MDA-MB-231 MlLpUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 Mn7tNVDDqG6P Mn71N:Kh\A>? NGP4V4xFVVOR NHnHXm9idHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= Moq0NlQ5OTB2OUe=
BT-549 NETnbphOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? NV3IcGZtOTEEoH7N Ml63N:Kh\A>? NWS2UnhOTE2VTx?= MUjhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? M4LBRVI1QDFyNEm3
MCF-7  M4\HNm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? MkXSNVDDqG6P MX2zxsBl MWTEUXNQ MoHVZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi M2C1WlI1QDFyNEm3
MCF-7 NV;qWZo6TnWwY4Tpc44hSXO|YYm= M2KwblUuPTBibl2= NXXkd|JOOjRiaB?= NXr2WXhvTE2VTx?= NUL4WXNPemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>? Mln3NlQ{PjZ2MEe=
CTS MnjDRZBweHSxc3nzJGF{e2G7 M1f3PVDjiJN2MDDuUeKh MmTkOFghcA>? MmPlbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWSyOFI1PDR{OR?=
OCI-AML3  NHH3dXdCeG:ydH;zbZMhSXO|YYm= MnTRNQKBmzRyIH7NxsA> NUTCfGQzPDhiaB?= M{OwRolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWnoSFhSOjR{NES0Nlk>
U937 MWPBdI9xfG:|aYOgRZN{[Xl? NXvZdFJOOOLCk{SwJI5OyqB? M4rIPFQ5KGh? NVXOSmhJcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnO4NlQzPDR2Mkm=
PC3 M1f0ZmFxd3C2b4Ppd{BCe3OjeR?= NXTFb4MxOC1zMECgcm0> NVvvTHQyOjRxNEigbC=> MmfQbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGnMPXUzPDF4M{KzNC=>
PC3-AR NFjjV2dCeG:ydH;zbZMhSXO|YYm= M13CSVAuOTByIH7N MXKyOE81QCCq NXTLSFU5cW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVvURlNDOjRzNkOyN|A>
PC3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSzUVRVOC1zMECgcm0> NULlfXJSOjRxNEigbC=> MnPlbY5lfWOnczDhZ4N2dXWuYYTpc44hd2Zic4XiS|EheG:ydXzheIlwdg>? NUfSdYNDOjRzNkOyN|A>
PC3-AR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\lR|AuOTByIH7N NYrlTph4OjRxNEigbC=> NHzxcoFqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNm0heGijc3W= NYfseGpXOjRzNkOyN|A>
PC3 MoDPSpVv[3Srb36gRZN{[Xl? MlG3NE0yODBibl2= NV76c3JIOjRiaB?= M3fHVJN2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu MlnnNlQyPjN{M{C=
PC3-AR MkfzSpVv[3Srb36gRZN{[Xl? NFLHNmUxNTFyMDDuUS=> MmXoNlQhcA>? NUDkWIpCe3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> NHqycGgzPDF4M{KzNC=>
OS-RC-2 M4iySGNmdGxiVnnhZoltcXS7IFHzd4F6 MXewMVExODBibl2= MoizNlQwPDhxN{KgbC=> Mlz3SG1UVw>? NYnKbnN[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUnG[YljOjRzNES3N|c>
OS-RC-2 M3fybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWK1NEBvVQ>? NID1cYI1QCCq NX75fYpUTE2VTx?= NYrFR4p{cW6mdXPld{BIOi:PIHHydoV{fA>? NHXYO3EzPDF2NEezOy=>
OS-RC-2 MUjBdI9xfG:|aYOgRZN{[Xl? MXK1NEBvVQ>? NYHLcFJpPDhiaB?= M2XNOmROW09? M3HtRolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NFfDfVMzPDF2NEezOy=>
SK-N-AS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDDe4wx6oDVOECgcm0> M{DWcFQ5KGh? NXjaS5JxUUN3ME2yO{41KG6P MV[yOFA6QDd7OR?=
SK-N-DZ MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHHNQKBmzhyIH7N MUK0PEBp MnzWTWM2OD1{MT65JI5O NWT6SWs{OjRyOUi3PVk>
SK-N-SH MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHRRpMx6oDVOECgcm0> MYm0PEBp NXL6S3NjUUN3ME23Nk4{KG6P NWm5RmozOjRyOUi3PVk>
SK-N-BE NGOxUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PNfVDjiJN6MDDuUS=> M2TBTlQ5KGh? NXj1THJ6UUN3ME23OU41KG6P MmnXNlQxQTh5OUm=
SK-N-AS MXzBdI9xfG:|aYOgRZN{[Xl? NUXHVlN[OOLCk{iwJI5O MUe0PEBp Mk[zdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MVGyOFA6QDd7OR?=
SK-N-DZ M{DrUmFxd3C2b4Ppd{BCe3OjeR?= M3nJelDjiJN6MDDuUS=> M3\oPFQ5KGh? NEj6RVVxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NYXDb4puOjRyOUi3PVk>
SK-N-SH MYDBdI9xfG:|aYOgRZN{[Xl? M3T1VFDjiJN2MDDuUS=> NEjkdm41QCCq Mm\SdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NHS3T4czPDB7OEe5PS=>
SK-N-BE NUHIXIVqSXCxcITvd4l{KEG|c3H5 MUWw5qCUPDBibl2= MU[0PEBp MnWxdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NFLqS24zPDB7OEe5PS=>
SK-N-AS M33MbmZ2dmO2aX;uJGF{e2G7 NXqyTXdsOOLCk{iwJI5O M4DQdFQ5KGh? M{OxNYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NYHNNWJIOjRyOUi3PVk>
SK-N-DZ M2TEcmZ2dmO2aX;uJGF{e2G7 M4PHT|DjiJN6MDDuUS=> M2TmelQ5KGh? MmrkbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MljkNlQxQTh5OUm=
SK-N-SH NFH0[pBHfW6ldHnvckBCe3OjeR?= MkPmNQKBmzRyIH7N NFS2Z4U1QCCq NHvDUopqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR NF\tN4IzPDB7OEe5PS=>
SK-N-BE NHz2RnhHfW6ldHnvckBCe3OjeR?= NGfnU5ox6oDVNECgcm0> MXi0PEBp MkXDbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NFfoV4kzPDB7OEe5PS=>
HCC-LM3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGxMVExODBibl2= MnHSNlQwPDhxN{KgbC=> NUHrbpE1TE2VTx?= M3\hVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVSyOFA6Ozl3Nh?=
HepG2 NXnsXpJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxMVExODBibl2= MVuyOE81QC95MjDo M{L2SmROW09? NYjlN3ZZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmjzNlQxQTN7NU[=
SMMC-7721 NYPHN482T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z4OFEuOTByMDDuUS=> M{n1cFI1NzR6L{eyJIg> M1:5O2ROW09? MnnubY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYWyOFA6Ozl3Nh?=
HCC-LM3 MlHJRZBweHSxc3nzJGF{e2G7 NGiyZVQ2OCCwTR?= NEHVbmQ1QCCq NEH3WlNFVVOR MojWbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> MmH0NlQxQTN7NU[=
HepG2 NYXtbW5kSXCxcITvd4l{KEG|c3H5 NYrJcFB5PTBibl2= NEH2dZI1QCCq MYnEUXNQ NHzncppqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? NFvmd|YzPDB7M{m1Oi=>
SMMC-7721 Mn3XRZBweHSxc3nzJGF{e2G7 MXm1NEBvVQ>? NYTuT2YzPDhiaB?= M4PuWWROW09? NVHLVY0xcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? NYLKXI8yOjRyOUO5OVY>
HCC-LM3 MnGwSpVv[3Srb36gRZN{[Xl? MlPHOVAwOTByIH7N MVGyOEBp NEfEfIhFVVOR M3f4WoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= M2nwWVI1ODl|OUW2
HepG2 NWCxT245TnWwY4Tpc44hSXO|YYm= MYO1NE8yODBibl2= NIPpOVQzPCCq NF;sem5FVVOR M3TJXoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= M2G4[VI1ODl|OUW2
SMMC-7721 NYXkb5RKTnWwY4Tpc44hSXO|YYm= NXPiNHRXPTBxMUCwJI5O NGq0R4MzPCCq M3TGTWROW09? Mlnk[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= M3SwS|I1ODl|OUW2
HCC-LM3 NVT5NW9xTnWwY4Tpc44hSXO|YYm= M2f0U|UxNzFyMDDuUS=> NYKwPFhQOjRiaB?= NGrLU2NFVVOR NYH4NYp[\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= MXGyOFA6Ozl3Nh?=
HepG2 NWPCOo04TnWwY4Tpc44hSXO|YYm= NXj5Z5BFPTBxMUCwJI5O NXSyV3pGOjRiaB?= MXnEUXNQ Mo\C[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? MVOyOFA6Ozl3Nh?=
SMMC-7721 MojYSpVv[3Srb36gRZN{[Xl? M4n5XlUxNzFyMDDuUS=> MXWyOEBp NVK4dog3TE2VTx?= MVvkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v MUeyOFA6Ozl3Nh?=
FaDu NXzkfopXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonrNVAx6oDHbl2= NF\Ib4I5NzFyL{GyJIg> NYfISXE{\Gm|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl MXSyOFAzPjR6Mh?=
FaDu MYnGeY5kfGmxbjDBd5NigQ>? MWOxNFDjiIWwTR?= MXOyM|QwQC9zMjDo NFTVR5dqdmS3Y3XkJJAzOVejZkGvR4lxOcLiZYjwdoV{e2mxbh?= NGfsOGczPDB{NkS4Ni=>
PC-3  M2mxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfMTJQxNTFyIN88US=> MnT0NlQwPDhxN{KgbC=> NYP1SY5[cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIDBNJQzOzl7MUKxOi=>
LNCaP NUTLcmNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfyNE02KM7:TR?= NFLZPZkzPC92OD:3NkBp M2LrfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlHpNlM6QTF{MU[=
RWPE-1  M{LKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfhNE0zOCEQvF2= MmPvNlQwPDhxN{KgbC=> MWjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUD2[YNqOjN7OUGyNVY>
Capan-1 NULZXpJ4TnWwY4Tpc44hSXO|YYm= NGW3NGMzPS93MD:xNFAhdk1? NF;oWnY5NzJ2L{S4JIg> MUPEUXNQ M4LEcYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= MXmyN|kzOjh6Nh?=
L3.6pl NIXzZWNHfW6ldHnvckBCe3OjeR?= MnvXNlUwPTBxMUCwJI5O M{K1dVgwOjRxNEigbC=> NHP2VoJFVVOR Ml7s[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= NWfOXlU5OjN7MkK4PFY>
CFPAC-1  NX7ObmtPTnWwY4Tpc44hSXO|YYm= MWiyOU82OC9zMECgcm0> NEHGW5o5NzJ2L{S4JIg> MUfEUXNQ NYexfmZG\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> MlLwNlM6OjJ6OE[=
Capan-1 M3\RPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCyOU82OC9zMECgcm0> MojWOFghcA>? NIHwSWdFVVOR NYC0dGx1emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX\FPFg5OjN7MkK4PFY>
L3.6pl NE[0TYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXTVXIzPS93MD:xNFAhdk1? NFjifmg1QCCq NFXnclJFVVOR M1eyfJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFHHTJQzOzl{Mki4Oi=>
CFPAC-1  MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfOcYYzPS93MD:xNFAhdk1? NX\nd4tzPDhiaB?= M2LzfmROW09? Ml23doVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NH3r[VQzOzl{Mki4Oi=>
Capan-1 NVnmfopXSXCxcITvd4l{KEG|c3H5 NHnyVpYzPS93MD:xNFAhdk1? MnjrOFghcA>? Mlm1SG1UVw>? MmrzbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUSyN|kzOjh6Nh?=
L3.6pl Ml7oRZBweHSxc3nzJGF{e2G7 M1PPV|I2NzVyL{GwNEBvVQ>? MnLHOFghcA>? MYDEUXNQ NUGwfoVHcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlzSNlM6OjJ6OE[=
CFPAC-1  MX3BdI9xfG:|aYOgRZN{[Xl? Mom5NlUwPTBxMUCwJI5O Mk\zOFghcA>? Ml7PSG1UVw>? NX\1UGxNcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn;iNlM6OjJ6OE[=
HN22 MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUewMVIxKG6P NXPmOmh6OjRxNEigbC=> MmDuSG1UVw>? NGT6d|lqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz NV;wOVg1OjN6N{eyN|U>
HSC4  MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj6VmRyOC1{MDDuUS=> NF23fVMzPC92ODDo MUTEUXNQ MnLmbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NUe1WmdXOjN6N{eyN|U>
HN22 NVHpTnQySXCxcITvd4l{KEG|c3H5 NEnRe2QxNTJyIH7N M1HkPFQ5KGh? MWPEUXNQ MVjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MlTINlM5Pzd{M{W=
HSC4  MXzBdI9xfG:|aYOgRZN{[Xl? MXuwMVIxKG6P MXi0PEBp NIq1cplFVVOR MUTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NWXCRW55OjN6N{eyN|U>
HN22 NIHtUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\3fIkxNTJyIH7N NV\OfpViPDhiaB?= M1ewb2ROW09? NF[3eWhqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> MkHsNlM5Pzd{M{W=
HSC4  NUHTOJlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmwMVIxKG6P M2rVV|Q5KGh? M3XhNmROW09? MXvpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= MkXPNlM5Pzd{M{W=
HN22 NGfPSFhHfW6ldHnvckBCe3OjeR?= MVywMVIxKG6P MYC0PEBp Ml\1SG1UVw>? MnvJd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg M4j4PFI{QDd5MkO1
HSC4  MUDGeY5kfGmxbjDBd5NigQ>? M3;vN|AuOjBibl2= NWPZXWxMPDhiaB?= MnPmSG1UVw>? M2fKdJN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> MlTONlM5Pzd{M{W=
Cal62 M{i0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN|INMxJFQhdk1? NF\kNZEzOzh{NEC2OC=>
Hth7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ZUWlEPTB;MUWgxtEhOiCwTR?= NHq0dVkzOzh{NEC2OC=>
Hth83 NHXWVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD3TWM2OD1|NDFCtUA2KG6P MUOyN|gzPDB4NB?=
C643 NVnNWXcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zMPWlEPTB;N{GgxtEhOTBibl2= M2fnSlI{QDJ2ME[0
SW1736 NUe2SW9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH3N|lCUUN3ME2zOUDDuSB6IH7N MYqyN|gzPDB4NB?=
T241 M3qw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLnSm56UUN3ME22OUDDuSB5IH7N NHj4do4zOzh{NEC2OC=>
T351 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLIRmNzUUN3ME21NEDDuSBzMDDuUS=> M{Tnd|I{QDJ2ME[0
BHP2-7 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN5INMxJFYhdk1? NIjiT4gzOzh{NEC2OC=>
T238 NUjL[2R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfNO|ZKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? MmPnNlM5OjRyNkS=
HCT8 NXfKZ5JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ezTlczKGh? NWXLVXVYTE2VTx?= NFe2cHlKSzVyPUGyMlnjiIoEsfMAjVEvQSCwTR?= NGntR3ozOzJ7OUO4PC=>
H630 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljvO|IhcA>? NFX2PZNFVVOR NULjcWpXUUN3ME2xNk416oDLwsJihKk{NjFibl2= MWiyN|I6QTN6OB?=
cH630 5-FU-res M1n5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDVZWNQPzJiaB?= MWHEUXNQ MUfJR|UxRTF3LkZihKnDueLCiUGuNkBvVQ>? MnrPNlMzQTl|OEi=
HCT116 M{LlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\FOFczKGh? MXfEUXNQ MkLaTWM2OD1zMD635qCKyrIkgJmyMlIhdk1? NILxZ4IzOzJ7OUO4PC=>
HCT116 p53−/− MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH6yXmU4OiCq M1PXNWROW09? MoC3TWM2OD16LkdihKnDueLCiUGuO{BvVQ>? NITad4MzOzJ7OUO4PC=>
dHCT116 p21−/− M2T0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPRO|IhcA>? M{[wO2ROW09? MmrkTWM2OD13LkpihKnDueLCiUGuN{BvVQ>? NF7yZXYzOzJ7OUO4PC=>
HT29 NXf1NJJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fkb|czKGh? NVzHfXBpTE2VTx?= M2LDfWlEPTB;MU[uN-KBkcLz4pEJNk4{KG6P NIr3WWczOzJ7OUO4PC=>
LoVo MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK3NkBp NYPvTpRYTE2VTx?= NHv6W2xKSzVyPUWuNgKBkcLz4pEJNE43KG6P NI\RSYQzOzJ7OUO4PC=>
RKO M2XEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[yc4Y4OiCq Mn33SG1UVw>? M33kcmlEPTB;Nz655qCKyrIkgJmyMlIhdk1? NF;sSmIzOzJ7OUO4PC=>
SW480 NIjtd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\0Sm5zPzJiaB?= MWPEUXNQ MnLpTWM2OD1zNz615qCKyrIkgJmwMlghdk1? NYHvNnNQOjN{OUmzPFg>
eSW620 NXS2TItGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPIO|IhcA>? M{CxPWROW09? M4\Tc2lEPTB;OT6x5qCKyrIkgJmyMlEhdk1? M3XLRVI{Ojl7M{i4

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

お薦めの試験操作(参考用のみ)

細胞試験: [1]
+ 展開
  • 細胞株: MOLT-4 cell lines and Reh (pre-B cells)
  • 濃度: 50 nM
  • 反応時間: 48 hours
  • 実験の流れ: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • 製剤: Dextrose 5% in water
  • 投薬量: 10 mg/kg, 20 mg/kg
  • 投与方法: Administered via i.p. injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 349.43
化学式

C21H23N3O2

CAS No. 404950-80-7
保管
in solvent
別名 NVP-LBH589

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How to reconstitute the compound for in vivo mice study?

  • 回答:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Panobinostat (LBH589)を買う | Panobinostat (LBH589) ic50 | Panobinostat (LBH589)供給者 | Panobinostat (LBH589)を購入する | Panobinostat (LBH589)費用 | Panobinostat (LBH589)生産者 | オーダーPanobinostat (LBH589) | Panobinostat (LBH589)化学構造 | Panobinostat (LBH589)分子量 | Panobinostat (LBH589)代理店
×

大阪市内で「G20サミット」が開催されることに伴い、大阪府内で大規模な交通規制が行われる影響で、6月26日(水)から7月1日(月)までの間、下記地域へ出荷が行えなくなります。
対象地域
大阪府(全域)、兵庫県(芦屋市、尼崎市、伊丹市、西宮市)
上記地域より西の地域につきましては納期の遅延が予想されます。
また、国際便も遅延が予想されているため国内在庫がない製品の納期が一週間程度遅れる可能性がございます。
ご不便をおかけいたしますが、宜しくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID